TW200626722A - 11 &bgr'-HSDI antisense compounds - Google Patents

11 &bgr'-HSDI antisense compounds

Info

Publication number
TW200626722A
TW200626722A TW094141818A TW94141818A TW200626722A TW 200626722 A TW200626722 A TW 200626722A TW 094141818 A TW094141818 A TW 094141818A TW 94141818 A TW94141818 A TW 94141818A TW 200626722 A TW200626722 A TW 200626722A
Authority
TW
Taiwan
Prior art keywords
bgr
hsdi
antisenseoligonucleotides
antisense compounds
provides
Prior art date
Application number
TW094141818A
Other languages
Chinese (zh)
Inventor
Makoto Koizumi
Manabu Abe
Kazushi Araki
Ryo Okuyama
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of TW200626722A publication Critical patent/TW200626722A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01146—11-Beta-hydroxysteroid dehydrogenase (1.1.1.146)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/054—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function
    • A01K2217/058—Animals comprising random inserted nucleic acids (transgenic) inducing loss of function due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Abstract

This invention provides antisenseoligonucleotides or the pharmaceutically acceptable slats thereof, which comprises 15~19 bases against the target nucleic acid molecules coding 11 &bgr'-hydroxysteroid dehydrogenase 1, wherein at least one of the ribose of the antisenseoligonucleotides is 2'-O,4'-C-alkylenelated, 2'-O-alkylated, 2'-O-alkenylated or 2'-O-alkynylated. This invention also provides a pharmaceutical composition and inhibitor for expression of 11 &bgr'-hydroxysteroid dehydrogenase 1, which comprises the said antisenseoligonucleotides.
TW094141818A 2004-11-30 2005-11-29 11 &bgr'-HSDI antisense compounds TW200626722A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004345270 2004-11-30

Publications (1)

Publication Number Publication Date
TW200626722A true TW200626722A (en) 2006-08-01

Family

ID=36564941

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094141818A TW200626722A (en) 2004-11-30 2005-11-29 11 &bgr'-HSDI antisense compounds

Country Status (2)

Country Link
TW (1) TW200626722A (en)
WO (1) WO2006059507A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029619A1 (en) * 2006-09-07 2008-03-13 Daiichi Sankyo Company, Limited Ena antisense oligonucleotide having sequence-specific action
WO2009048903A1 (en) * 2007-10-08 2009-04-16 Bristol-Myers Squibb Company 11 beta hydroxysteroid dehydrogenase type 1
EP3010514B1 (en) 2013-06-16 2021-01-20 National University Corporation Tokyo Medical and Dental University Double-stranded antisense nucleic acid with exon-skipping effect
ES2930274T3 (en) 2014-05-19 2022-12-09 Knc Laboratories Co Ltd Nucleic acid drug to induce skipping of exonic variants of the CD44 gene and increase expression of normal-type CD44 mRNA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (en) * 1997-03-07 2006-03-15 武 今西 Novel bicyclonucleosides and oligonucleotide analogues
EP1152009B2 (en) * 1999-02-12 2017-09-06 Daiichi Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues
DE19951970A1 (en) * 1999-10-28 2001-05-03 Bionetworks Gmbh Medicines for tolerance induction
SE0001899D0 (en) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
EP1309697A2 (en) * 2000-07-05 2003-05-14 Bayer Aktiengesellschaft Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
JP2003192692A (en) * 2001-10-18 2003-07-09 Sankyo Co Ltd Vegf antisense compound
US20030198965A1 (en) * 2002-04-19 2003-10-23 Isis Pharmaceuticals Inc. Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression
JP2004129650A (en) * 2002-08-13 2004-04-30 Sankyo Co Ltd New antisense compound
JP2004187609A (en) * 2002-12-12 2004-07-08 Sankyo Co Ltd Method for determining optimal antisense sequence
JP2004315451A (en) * 2003-04-17 2004-11-11 Sankyo Co Ltd Pharmaceutical containing vascular endothelial growth factor antisense compound

Also Published As

Publication number Publication date
WO2006059507A1 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
HK1062677A1 (en) 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2003080582A3 (en) Fredericamycin derivatives
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
EP1942948A4 (en) Compositions and methods for inhibiting expression of nav1.8 gene
MY143599A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
TN2009000225A1 (en) Compounds and compositions as protein kinase kinase inhibitors
TW200722100A (en) A therapeutic agent for a β related disorders
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005044199A3 (en) Combination of proton pump inhibitor and sleep aid
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
BRPI0515721A (en) use of a src kinase inhibitor and a bcr-abl inhibitor, pharmaceutical composition and combination
WO2008073452A8 (en) Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
WO2008003028A3 (en) Pharmaceutical compositions comprising droxidopa
WO2008034796A3 (en) Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2008042282A3 (en) Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
TW200628458A (en) Metasubstituted thiazolidinones, their manufacture and use as a drug
WO2001056573A8 (en) Use of cox-2 inhibitors as gastroprokinetics
BR0316723A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA04003611A (en) Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases.
TW200626722A (en) 11 &bgr'-HSDI antisense compounds
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
WO2001081316A3 (en) Substituted phenyl farnesyltransferase inhibitors